论文信息 - An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. - 字舞流文

An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.

M. Kreissl | M. Schlumberger | P. Schőffski | M. Brose | B. Nelkin | D. Ball | B. Jarzab | L. Licitra | P. Schöffski | S. Sherman | R. Elisei | S. Müller | M. Shah | V. Medvedev | B. Niederle | L. Wirth | C. Hessel | Y. Yaron | E. Cohen | L. Licitra | H. Ali | Manisha H. Shah | Ezra E. W. Cohen | Lori J. Wirth | Haythem Y. Ali | E. Cohen